Involving Nonmembrane Bound Receptor Binding Or Protein Binding Other Than Antigen-antibody Binding Patents (Class 435/7.8)
  • Patent number: 10338065
    Abstract: A method is taught for the accurate determination of the premature rupture of membranes (PROM), defined as spontaneous rupture of membranes before the onset of uterine contractions. More specifically, a lateral flow assay strip tests for at least two antigens to greatly limit or eliminate the possibility of false negatives. A built-in timer in the cassette holding the lateral flow assay further increases the accuracy of the test. A collection buffer vial with self-contained shipping and dropper caps and built-in stand is also taught.
    Type: Grant
    Filed: June 30, 2014
    Date of Patent: July 2, 2019
    Assignee: Clinical Innovations, LLC
    Inventors: William Dean Wallace, Glen Ford
  • Patent number: 10279030
    Abstract: The present invention includes compositions and methods for making and using anti DC-ASGPR antibodies that can, e.g., activate DCs and other cells.
    Type: Grant
    Filed: September 14, 2016
    Date of Patent: May 7, 2019
    Assignee: Baylor Research Institute
    Inventors: SangKon Oh, Dapeng Li
  • Patent number: 10080799
    Abstract: Disclosed herein are compositions and methods for eliciting immune responses against HCV antigens. In particular embodiments, the compounds and methods elicit immune responses against all or a segment of HCV glycoprotein E1 and/or HCV glycoprotein E2.
    Type: Grant
    Filed: February 11, 2011
    Date of Patent: September 25, 2018
    Assignee: Arizona Board of Regents on Behalf of Arizona State University
    Inventors: Hugh S. Mason, Seong Hee Bhoo, Sun Hee Rosenthal, Charles J. Arntzen
  • Patent number: 9995680
    Abstract: Provided herein are compositions and methods including the step of thermally scanning a sample that can be used and implemented to detect the presence of and/or concentration of a molecule in a sample.
    Type: Grant
    Filed: November 4, 2015
    Date of Patent: June 12, 2018
    Assignee: Auburn University
    Inventors: Christopher J. Easley, Joonyul Kim, Juan Hu, Mark D. Holtan, Subramaniam Somasundaram, Curtis Shannon
  • Patent number: 9937235
    Abstract: Lipidated peptides, analogs of both forms of the prolactin-releasing peptide, PrRP31 and PrRP20, represent anorexigenic compounds that lower food intake and function in the brain after peripheral administration. The analogs PrRP31 and PrRP20 lipidated at the N-terminus by myristic or palmitic acids bind with high affinity to the endogenous receptor GPR10 in the rat pituitary cell line RC-4B/C and CHO cell line with transfected human receptor. These lipidated peptides also significantly decrease, in a dose-dependent manner, the food intake in fasted mice and have similar effects in comparable doses as centrally administered natural PrRP31, these effects are, however, stronger and longer lasting. Lipidation of an effective anorexigenic neuropeptide PrRP induces a central effect after peripheral administration and thus makes the lipidated analogs of PrRP a promising anti-obesity drug.
    Type: Grant
    Filed: July 11, 2013
    Date of Patent: April 10, 2018
    Assignee: USTAV ORGANICKE CHEMIE A BIOCHEMIE AKADEMIE VED CR, V.V.I.
    Inventors: Lenka Maletinska, Blanka Zelezna, Miroslava Blechova, Andrea Popelova
  • Patent number: 9907850
    Abstract: The present invention concerns methods and compositions for treating or preventing a bacterial infection, particularly infection by a Staphylococcus bacterium. The invention provides methods and compositions for stimulating an immune response against the bacteria. In certain embodiments, the methods and compositions involve a non-toxigenic Protein A (SpA) variant or an antibody directed thereto.
    Type: Grant
    Filed: December 14, 2015
    Date of Patent: March 6, 2018
    Assignee: The University of Chicago
    Inventors: Olaf Schneewind, Alice Cheng, Dominique M. Missiakas, Hwan Keun Kim
  • Patent number: 9766247
    Abstract: Provided are a method of analyzing ubiquitin-proteasome activity with respect to a target polypeptide and a method of screening a ubiquitin-proteasome inhibitor. According to the provided methods, the pattern of lysis of a target polypeptide by a ubiquitin-proteasome in target cells may be quantitatively analyzed in a rapid and highly sensitive way, a ubiquitin-proteasome inhibitor may be screened in a rapid and highly sensitive way, and an anticancer agent and the activity thereof may be rapidly screened.
    Type: Grant
    Filed: October 14, 2014
    Date of Patent: September 19, 2017
    Assignee: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Eun Joo Song, Hyunjung Lee, Eunmi Ban, Eunice EunKyeong Kim, Young Sook Yoo
  • Patent number: 9453074
    Abstract: The present invention includes compositions and methods for making and using anti DC-ASGPR antibodies that can, e.g., activate DCs and other cells.
    Type: Grant
    Filed: April 16, 2014
    Date of Patent: September 27, 2016
    Assignee: Baylor Research Institute
    Inventors: Sangkon Oh, Dapeng Li
  • Patent number: 9382307
    Abstract: Methods and compositions for measuring the amount of vitamin D derivatives are disclosed. Fluorescence Resonance Energy Transfer (FRET) in combination with a modified ligand-binding domain of the vitamin D receptor (LBD-VDR) to measure vitamin D derivatives are also disclosed.
    Type: Grant
    Filed: October 9, 2013
    Date of Patent: July 5, 2016
    Assignee: OPKO IRELAND GLOBAL HOLDINGS, LTD.
    Inventors: P. Martin Petkovich, Christian F. Helvig
  • Patent number: 9383368
    Abstract: Methods for determining the presence of heparin/platelet factor 4 antibodies in a sample suspected to contain heparin/platelet factor 4 antibodies are provided, along with apparatus suitable for performing the methods. The method depends upon a color visualization indicating the presence or absence of heparin/platelet factor 4 antibodies in the sample. Preferred methods comprise contacting the sample with particles being complexed to platelet factor 4 (PF4) and which particle-complexed PF4 reacts specifically with heparin/platelet factor 4 antibodies, passing the sample/particle mixture through a filter, and then analyzing the color of the filtrate. The presence of heparin/platelet factor 4 antibodies in the sample is established where the color of the filtrate is substantially different from the color of the receptor-bearing particles.
    Type: Grant
    Filed: May 12, 2014
    Date of Patent: July 5, 2016
    Assignee: Akers Biosciences, Inc.
    Inventor: Susan Andrelczyk
  • Patent number: 9290793
    Abstract: The present invention provides, among other things, methods for the characterization of recombinant Heparan N-Sulfatase (HNS) during manufacture. The present invention uses capillary zone electrophoresis to determine the charge profile, isoform distribution, and/or glycan profile of recombinant HNS; and represents a quality feature for the batch consistency, storage stability, biological half-life, pharmacokinetic, pharmacodynamic and biological activity of the enzyme. In particular, such characterization methods may be beneficial to optimize conditions and ensure consistency for the manufacture of HNS for the treatment of a patient diagnosed with Sanfilippo syndrome using enzyme replacement therapy.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: March 22, 2016
    Assignee: Shire Human Genetic Therapies, Inc.
    Inventor: Daniel Roseman
  • Patent number: 9234040
    Abstract: The present invention includes compositions and methods for increasing the effectiveness of antigen presentation using a DCIR-specific antibody or fragment thereof to which an antigen is attached that forms an antibody-antigen complex, wherein the antigen is processed and presented by a dendritic cell that has been contacted with the antibody-antigen complex.
    Type: Grant
    Filed: October 3, 2013
    Date of Patent: January 12, 2016
    Assignee: Baylor Research Institute
    Inventors: Gerard Zurawski, Jacques F. Banchereau, Eynav Klechevsky, Sandra Zurawski, Anne-Laure Flamar
  • Patent number: 9212219
    Abstract: The present invention concerns methods and compositions for treating or preventing a bacterial infection, particularly infection by a Staphylococcus bacterium. The invention provides methods and compositions for stimulating an immune response against the bacteria. In certain embodiments, the methods and compositions involve a non-toxigenic Protein A (SpA) variant or an antibody directed thereto.
    Type: Grant
    Filed: July 18, 2014
    Date of Patent: December 15, 2015
    Assignee: The University of Chicago
    Inventors: Olaf Schneewind, Alice Cheng, Dominique M. Missiakas, Hwan Keun Kim
  • Patent number: 9161520
    Abstract: The present invention provides transgenic non-human animals and non-human mammalian somatic and germ cells harboring a human DNA sequence encoding Alzheimer's Disease (AD) derived tau protein, capable of inducing AD pathology in transgenic animals. Alzheimer's tau protein is expressed on specific genetic backgrounds allowing also simulation of different human diseases including hypertension, diabetes, hyper-cholesterolemia, which are associated with neurodegeneration and are considerable risk factors for AD development. Transgenic animals and cells of the invention exhibit neurofibrillary pathology and may serve as in vivo and in vitro assay systems for screening and developing therapeutic and preventive substances and also diagnostic markers and probes for tauopathies and AD.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: October 20, 2015
    Assignee: Axon Neuroscience SE
    Inventors: Eva Kontsekovà, Peter Filipcik
  • Patent number: 9164109
    Abstract: Methods of determining levels of unbound metabolites are disclosed. Probes derived from fatty acid binding protein muteins are described that bind preferentially to a number of unbound metabolites including oleate, stearate, linoleate, palmitate, arachidonate and unconjugated bilirubin. A profile for a patient is determined using one or more of the described probes. The profile is useful in diagnosis of disease, particularly myocardial infarction, non-alcoholic fatty liver disease (NAFLD), diabetes, stroke, sepsis and neonatal jaundice. The responses of multiple probes to a test sample are used to classify the degree of acute coronary syndrome by comparison to multi-probe profiles generated from unstable angina, non ST elevation myocardial infarction, and ST elevation myocardial infarction.
    Type: Grant
    Filed: October 26, 2007
    Date of Patent: October 20, 2015
    Inventors: Alan Marc Kleinfeld, Andrew Henry Huber, James Patrick Kampf, Thomas Kwan, Baolong Zhu
  • Patent number: 9095540
    Abstract: The present invention concerns methods and compositions for treating or preventing a bacterial infection, particularly infection by a Staphylococcus bacterium. The invention provides methods and compositions for stimulating an immune response against the bacteria. In certain embodiments, the methods and compositions involve a non-toxigenic Protein A (SpA) variant. In some embodiments, the methods and compositions involve SdrD, ClfA, and/or FnbpB polypeptides.
    Type: Grant
    Filed: September 9, 2011
    Date of Patent: August 4, 2015
    Assignee: The University of Chicago
    Inventors: Olaf Schneewind, Alice G. Cheng, Dominique M. Missiakas, Hwan Keun Kim, Hye-Young Kim
  • Publication number: 20150147752
    Abstract: The present invention relates to novel iridium-based Ir(III) luminescent complexes, conjugates comprising these complexes as a label and their application, e.g. in the electrochemiluminescence based detection of an analyte.
    Type: Application
    Filed: January 30, 2015
    Publication date: May 28, 2015
    Inventors: Frank Bergmann, Robert Cysewski, Luisa de Cola, Sebastian Dziadek, Jesus Miguel Fernandez Hernandez, Hans-Peter Josel, Elena Longhi, Christoph Seidel
  • Publication number: 20150140010
    Abstract: The present invention relates to methods for diagnosing and treating focal segmental glomerulosclerosis. More particularly, the present invention relates to a method for determining whether a subject is at risk of having or developing a focal segmental glomerulosclerosis (FSGS) comprising the step consisting of determining the level of calcium/calmodulin-dependent serine protein kinase (CASK) in a blood sample obtained from the subject. The present invention also relates to an agent effective to inhibit the binding of CASK to hCD98 present on the surface of podocytes for use in the prevention or treatment of focal segmental glomerulosclerosis (FSGS) in a subject in need thereof.
    Type: Application
    Filed: May 22, 2013
    Publication date: May 21, 2015
    Applicants: INSERM 9INSTITUT NATIONAL DE LA SANTE ET DE LA R- ECHERCHE MEDICALE), UNIVERSITE PARIS-SUD XI, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
    Inventors: Antoine Durrbach, Hanz Lorenzo, Severine Beaudreuil
  • Publication number: 20150141345
    Abstract: This invention provides novel compounds and methods for promoting cell survival and/or plasticity, especially in neuronal cells, by targeting the microtubule End Binding (EB) proteins and other associated proteins (e.g., drebrin). Methods for identifying potential modulators of cell death/plasticity are also described.
    Type: Application
    Filed: March 12, 2013
    Publication date: May 21, 2015
    Inventors: Illana Gozes, Saar Oz, Jacqueline Woang Cheing Tiong
  • Publication number: 20150140575
    Abstract: The invention is directed to a method of determining whether a non-purified sample contains a target protein bound to a ligand of interest comprising the steps of: a) exposing said non-purified sample to a temperature which is capable of causing or enhancing precipitation of the unbound target protein to a greater extent than it is capable of causing or enhancing precipitation of the target protein bound to said ligand; b) processing the product of step a) in order to separate soluble from insoluble protein; and c) analysing either or both the soluble and insoluble protein fractions of step b) for the presence of target protein, wherein said target protein is not detected on the basis of enzymatic activity of a tag, peptide, polypeptide or protein fused thereto. Particularly, the invention may be used to determine whether drugs can bind to their protein targets in samples derived from patients to ascertain whether a certain drug can be used in a therapy for that patient.
    Type: Application
    Filed: January 22, 2015
    Publication date: May 21, 2015
    Applicant: EVITRAPROTEOMA AB
    Inventor: Pär NORDLUND
  • Publication number: 20150140574
    Abstract: A modified polynucleotide has a different base sequence in at least one codon from a wild-type base sequence encoding a horseradish peroxidase polypeptide. The usage frequency of the modified codon of the polynucleotide corresponds to the codon usage frequencies of three filamentous fungal species in Humicola, Aspergillus, and Trichoderma. The polynucleotide is capable of expressing the polypeptide to be encoded in a filamentous fungus.
    Type: Application
    Filed: May 30, 2013
    Publication date: May 21, 2015
    Applicant: MEIJI SEIKA PHARMA CO., LTD.
    Inventors: Fumikazu Yokoyama, Kaoru Okakura, Atsushi Inoue, Koichiro Murashima, Toshiaki Nagasato, Koji Yanai, Akitaka Nakane
  • Patent number: 9034254
    Abstract: Disclosed is an antibacterial composition comprising titanium oxide particles immobilized with an antibody having affinity and cognitive power to a microorganism of interest, and a method for sterilizing the microorganism by using the same. In particular, the present invention relates to a method for preparing functional titanium oxide particles capable of recognizing a microorganism or a virus of interest, and a method for selectively and efficiently sterilizing the same by using the functional titanium oxide particles, and not for randomly sterilizing microorganisms or viruses by using conventional titanium oxide particles having no recognition power to a microorganism or a virus of interest.
    Type: Grant
    Filed: November 8, 2012
    Date of Patent: May 19, 2015
    Assignee: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Byoung Chan Kim, Jong Soo Jurng, Min Young Song
  • Publication number: 20150133441
    Abstract: This invention relates to agents that are inhibitors or activators of variant forms of endogenous proteins and novel methods of identifying such variants. Of particular interest are inhibitors and activators of endogenous protein variants, encoded by genes which have mutated, which variants often arise or are at least first identified as having arisen following exposure to a chemical agent which is known to be an inhibitor or activator of the corresponding unmutated endogenous protein.
    Type: Application
    Filed: June 6, 2014
    Publication date: May 14, 2015
    Inventor: Gerard M. Housey
  • Publication number: 20150135343
    Abstract: Certain embodiments are directed to polypeptide sensors. Certain aspects of the invention are directed to polypeptides for sensing or detecting GTP and GTP concentrations. In further aspects, the polypeptide sensor can measure GTP concentrations, with high temporal and spatial resolution.
    Type: Application
    Filed: May 18, 2013
    Publication date: May 14, 2015
    Applicant: The Board of Regents of the University of Texas Sy
    Inventors: Rui Sousa, Mitra Rana
  • Publication number: 20150125877
    Abstract: The present invention provides methods for analyzing a target compound from a biological sample. In one aspect, a method for analyzing a target compound in a biological sample can comprise delivering a biological sample through an affinity column, the affinity column having a binding ligand coupled to a stationary structural support, wherein the affinity column has a high density of the binding ligand per the stationary structural support and wherein the binding ligand has been preselected to cause weak affinity separation zonal retardation of the target compound from the biological sample forming a target compound fraction and a biological sample fraction and detecting the target compound by mass spectrometry.
    Type: Application
    Filed: September 4, 2014
    Publication date: May 7, 2015
    Inventors: Sten Ohlson, Anthony R. Torres
  • Patent number: 9023806
    Abstract: The invention concerns a peptide derived from intermediate filaments and an intermediate filament fragment capable of altering tubulin polymerization and used for inhibiting cell proliferation, and more particularly for obtaining medicines designed to prevent or treat diseases involving cell proliferation, such as cancers for example.
    Type: Grant
    Filed: April 21, 2005
    Date of Patent: May 5, 2015
    Assignees: Universite d'Angers, Institut National de la Sante et de la Recherche Medicale (Inserm), McGill University
    Inventors: Arnaud Bocquet, Joël Eyer, Alan Peterson
  • Publication number: 20150119475
    Abstract: The use of Akt3 as a biomarker for detecting the occurrence of epithelial-to-mesenchymal transition (EMT) in a subject, and the use of Akt3 inhibitors to treat cancer is disclosed herein. Also disclosed are various methods for detecting the occurrence of epithelial-to-mesenchymal transition (EMT) in a subject by measuring Akt3 expression and/or activity.
    Type: Application
    Filed: May 2, 2013
    Publication date: April 30, 2015
    Inventors: Jim Lorens, Crina Tiron
  • Publication number: 20150119270
    Abstract: The present invention discloses, inter alia, methods for labeling a target protein with an SHG-active probe for detection by second harmonic or sum-frequency generation in order to identify agents which bind to an allosteric site on the target protein thereby altering its structural conformation
    Type: Application
    Filed: April 25, 2013
    Publication date: April 30, 2015
    Inventor: Joshua S. Salafsky
  • Publication number: 20150119332
    Abstract: The present invention concerns methods and compositions related to type 3 phosphodiesterases (PDE3). Certain embodiments concern isolated peptides corresponding to various PDE3A isoforms and/or site-specific mutants of PDE3A isoforms, along with expression vectors encoding such isoforms or mutants. In specific embodiments, methods for identifying isoform-selective inhibitors or activators of PDE3 are provided, along with methods of use of such inhibitors or activators in the treatment of dilated cardiomyopathy, pulmonary hypertension and/or other medical conditions related to PDE3 effects on cAMP levels in different intracellular compartments.
    Type: Application
    Filed: November 14, 2013
    Publication date: April 30, 2015
    Applicants: UNIVERSITY OF UTAH RESEARCH FOUNDATION, THE UNITED STATES GOVERNMENT, AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
    Inventor: Matthew A. Movsesian
  • Publication number: 20150111199
    Abstract: Methods of studying, interrogating, analyzing, and detecting particles, substances, and the like with near field light are described. Methods of identifying binding partners, modulators, inhibitors, and the like of particles, substances, and the like with near field light are described. In certain embodiments, the methods comprise immobilizing or trapping the particle, substance, and the like.
    Type: Application
    Filed: March 15, 2013
    Publication date: April 23, 2015
    Inventors: Robert Hart, Bernardo Cordovez
  • Publication number: 20150111786
    Abstract: The invention provides methods of treating a meiotic kinase-associated disease, preferably the meiotic kinase HSET, by administering an inhibitor of the meiotic kinase. Preferably, the disease is associated with the presence of supernumerary centrosomes, such as cancer. Methods of inhibiting the growth of a tumor cell by contacting the cell with an inhibitor of a meiotic kinase, preferably HSET, are also provided. Screening methods for identifying inhibitors of the meiotic Kinase HSET are also provided. Methods of selecting subjects for treatment with an inhibitor of a meiotic kinase, such as HSET, are also provides.
    Type: Application
    Filed: January 7, 2015
    Publication date: April 23, 2015
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventor: David Pellman
  • Patent number: 9012161
    Abstract: The present invention provides methods for identifying a molecule that provides or enhances a sweet taste in the mouth and compositions containing such molecules. The methods involve determining the effect of a variety of known or new compounds on expression or functional activity of a glucose-transporter protein of the activity of an ATP-gated K+ channel (KATP) in a mammalian oral cell, taste cell, or heterologous cell that expresses the protein or channel.
    Type: Grant
    Filed: January 17, 2012
    Date of Patent: April 21, 2015
    Assignee: Monell Chemical Senses Center
    Inventor: Robert Franklin Margolskee
  • Publication number: 20150104808
    Abstract: Cysteine engineered monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules comprising one or more free cysteine amino acids are prepared by mutagenizing a nucleic acid sequence of a parent molecule and replacing one or more amino acid residues by cysteine to encode the cysteine engineered FN3 domain containing monospecific or bispecific molecules; expressing the cysteine engineered FN3 domain containing molecules; and recovering the cysteine engineered FN3 domain containing molecule. Isolated cysteine engineered monospecific or bispecific FN3 domain containing molecules may be covalently attached to a detection label or a drug moiety and used therapeutically.
    Type: Application
    Filed: October 13, 2014
    Publication date: April 16, 2015
    Inventors: Shalom Goldberg, Steven Jacobs, Tricia Lin
  • Publication number: 20150099660
    Abstract: Microfluidic devices and methods for using the same are provided. Aspects of the invention include microfluidic devices that include a separation medium and a pan-capture binding medium. The microfluidic devices are configured to subject a sample to two or more directionally distinct electric fields. Also provided are methods of using the devices as well as systems and kits that include the devices. The devices, systems and methods find use in a variety of different applications, including diagnostic and validation assays.
    Type: Application
    Filed: November 7, 2014
    Publication date: April 9, 2015
    Inventors: Amy E. Herr, Dohyun Kim
  • Patent number: 8999688
    Abstract: A polysaccharide-protein binding model of SBD, and a fibril-forming 14-residue peptide consisting of X1NNNX2X3NYQX4X5X6X7X8, wherein the X1 and X8 mean a pair of opposite charged amino acid residues, and the X2, X3, X4, X5, X6, or X7 means an amino acid residue is described. A mixture for diminishing a polysaccharide, comprising at least two starch binding domains (SBDs) and a polysaccharide in a helix form is also presented. A method of providing an oligosaccharide, and a method of producing an amyloid-like fibril and use thereof are further described.
    Type: Grant
    Filed: January 19, 2011
    Date of Patent: April 7, 2015
    Assignee: National Tsing Hua University
    Inventors: Margaret Dah-Tsyr Chang, Yuh-Ju Sun, Ping-Chiang Lyu, Shu-Chuan Lin, Wei-I Chou
  • Publication number: 20150094229
    Abstract: The present invention concerns a method for the screening of antibacterial substances comprising a step of determining the ability of a candidate substance to inhibit the activity of a purified enzyme selected from the group consisting of: (i) a D-aspartate ligase comprising a polypeptide having an amino acid sequence possessing at least 50% amino acid identity with an amino acid sequence selected from the group consisting of SEQ ID No 1 to SEQ ID No 10, or a biologically active fragment thereof; and (ii) a L,D-transpeptidase comprising a polypeptide having an amino acid sequence possessing at least 50% amino acid identity with the amino acid sequence of SEQ ID No 11, or a biologically active fragment thereof.
    Type: Application
    Filed: October 7, 2014
    Publication date: April 2, 2015
    Inventors: Jean-Luc MAINARDI, Laurent GUTMANN, Michel ARTHUR, Samuel BALLAIS, Jean Emmanuel HUGONNET, Claudine MAYER, Sabrina BIAROTTE-SORIN
  • Publication number: 20150094213
    Abstract: A method of comparative ligand mapping to identify peptide ligands presented by MHC positive cells that distinguish an infected/transfected cell from an uninfected/non-transfected cell is disclosed.
    Type: Application
    Filed: November 10, 2014
    Publication date: April 2, 2015
    Inventors: WILLIAM H. HILDEBRAND, HEATHER D. HICKMAN
  • Publication number: 20150093333
    Abstract: Embodiments herein report compositions, systems, methods, and uses for diagnosing and/or treating a condition in a subject. In certain embodiments, one or more peptides can be used as biomarker detectors for predicting onset or progression of disease. Some embodiments of the present invention report peptides capable of associating with MVs for predicting onset or progression of cancer in a subject. Other embodiments include methods of generating and or modifying peptides of use herein. Yet other embodiments herein report biomarker detectors capable of detecting agents associated with cancer progression, for example, metastasis.
    Type: Application
    Filed: August 30, 2012
    Publication date: April 2, 2015
    Inventors: Hang Yin, Jonel P. Saludes, Leslie Morton
  • Publication number: 20150093760
    Abstract: A cartridge for measuring a concentration of a glycated protein in a wide measurement range, a system for measuring a glycated protein, and a method of measuring a glycated protein using same.
    Type: Application
    Filed: October 1, 2014
    Publication date: April 2, 2015
    Inventors: Sang-kyu Kim, Kyung-mi Song, Jin-mi Oh, Youn-suk Choi
  • Patent number: 8993509
    Abstract: The present invention relates to agents, and methods for identifying compounds, which agents and compounds are effective in the treatment, and more particularly, that inhibit cachexia, and its associated or related disorders and conditions. In addition, the invention relates to compositions and methods for the use thereof in treating conditions that are characterized by cachexia, and its associated or related disorders and conditions and/or cachexia, and its associated or related disorders and conditions, such as for example, cancer cachexia and cachexia associated with AIDS, autoimmune disorders, drug addiction, alcoholism, chronic inflammatory disorders, cirrhosis of the liver, anorexia and neurodegenerative disease. In particular, the diagnostic marker and drug target of the invention is the ATGL Lipase, which can be inhibited by e.g. siRNAs and compounds with any of the following structures (I).
    Type: Grant
    Filed: March 31, 2010
    Date of Patent: March 31, 2015
    Inventors: Robert Zimmerman, Rudolf Zechner, Günther Haemmerle, Gerald Höfler, Suman Das, Achim Lass
  • Publication number: 20150079608
    Abstract: A method for detecting or quantifying an analyte, using a test strip for lateral flow type chromatography which contains a membrane and a detection part on which a capturing ligand that is to specifically bind to the analyte has been fixed on the membrane, includes: bringing an analyte contained in a sample into contact with a labeled ligand labeled with a phosphor that is to be excited by light having a wavelength from 600 nm to 800 nm to generate fluorescence, bringing a complex containing the analyte and the labeled ligand into contact with a capturing ligand at the detection part, and irradiating on the test strip light having a wavelength from 600 nm to 800 nm as an excitation light for the phosphor contained in the complex to generate fluorescence from the phosphor, and measuring a fluorescence intensity of the fluorescence.
    Type: Application
    Filed: April 2, 2013
    Publication date: March 19, 2015
    Applicants: ADTEC, INC., KONICA MINOLTA, INC.
    Inventors: Tsuruki Tamura, Katsuyoshi Takayama
  • Patent number: 8980571
    Abstract: The invention relates to methods of identifying a candidate compound which may inhibit estrogen receptor-dependent transcription or ?9-nAChR overexpression and proliferation of nicotine-derived-compound-induced breast cancer cells by using an activating protein 1 (AP1) polypeptide. The invention found that ?9-nAChR has an activating protein 1 (AP1)-binding site, that the ?9-nAChR promoter is located at the AP1-binding site, and that ERs specifically bind to the ?9-nAChR promoter at the AP1-binding site, indicating that ER-induced ?9-nAChR up-regulation plays a central role in the response to endogenous (E2) or exogenous (nicotine) stimulation.
    Type: Grant
    Filed: April 21, 2011
    Date of Patent: March 17, 2015
    Assignee: Taipei Medical University
    Inventors: Chia-Hwa Lee, Ya-Chieh Chang, Ching-Shyang Chen, Shih-Hsin Tu, Ying-Jan Wang, Li-Ching Chen, Yu-Jia Chang, Po-Li Wei, Hui-Wen Chang, Chien-Hsi Chang, Ching-Shui Huang, Chih-Hsiung Wu, Yuan-Soon Ho
  • Publication number: 20150064239
    Abstract: A method for identifying modulators of Interleukin 24 (IL-24) mediated apoptosis is disclosed. For IL-24 apoptosis to be effective, the cells should express Sigma 1 Receptor (S1R). Additionally apoptosis modulators can be identified by exposing biological cells to test compounds and monitoring for signs of endoplasmic reticulum (ER) stress protein expression; calcium mobilization; or reactive oxygen species (ROS) production.
    Type: Application
    Filed: September 3, 2014
    Publication date: March 5, 2015
    Inventors: Moira Sauane, Winchie Do
  • Publication number: 20150065554
    Abstract: Disclosed herein are methods of treating a patient at risk of developing or having a neurofibromatosis or a sporadic schwannoma. In exemplary embodiments, the method involves administering to a subject in need an effective amount of a modulator of a target related to neurofibromatosis. Also disclosed are screening assays involving the implementation of Merlin-null Schwann cells, and to compounds identified using same.
    Type: Application
    Filed: March 13, 2013
    Publication date: March 5, 2015
    Applicant: University of Central Florida Research Foundation, Inc.
    Inventor: Cristina Fernandez-Valle
  • Patent number: 8969023
    Abstract: Aspects of the invention relate to methods and compositions for treating Alzheimer's disease (AD). In some embodiments, the invention provides methods for screening and identifying compounds that selectively inhibit the targeting of the insulin-Akt signaling pathway by A? oligomers.
    Type: Grant
    Filed: June 10, 2009
    Date of Patent: March 3, 2015
    Assignee: Eleanore Bennett Charitable Trust #2
    Inventor: Henry W. Querfurth
  • Publication number: 20150051153
    Abstract: An environmentally sensitive membrane binding polypeptide, pH (low)-sensitive membrane peptide (pHLIP) has improved insertion kinetics balanced with solubility to selectively target acidic tissues.
    Type: Application
    Filed: July 13, 2011
    Publication date: February 19, 2015
    Inventors: Yana K. Reshetnyak, Oleg A. Andreev, Donald M. Engelman
  • Publication number: 20150044692
    Abstract: Identification and use of proteins fluorescently labeled and that undergo a change in fluorescence index upon binding bilirubin are described. Probes are disclosed which are labeled at a cysteine or lysine residue and also probes labeled at both cysteine and lysine with two different fluorophores. These probes are useful for determination of unbound bilirubin levels in a fluid sample.
    Type: Application
    Filed: August 24, 2012
    Publication date: February 12, 2015
    Inventors: Alan Marc Kleinfeld, Andrew Henry Huber, James Patrick Kampf, Thomas Kwan, Baolong Zhu
  • Publication number: 20150037817
    Abstract: The invention relates to a bifunctional tumor diagnostic reagent and a method for tumor diagnosis. The reagent consists of a protein shell specifically recognizing a cancer tissue and/or a cancer cell and an inorganic nano-core having the catalytic activity of a peroxidase. The bifunctional tumor diagnostic reagent has two functions, i.e., tumor specific identification and color development, and enables the tumor specific identification and the color development to be completed in one step, and the operation of the process is simple and convenient.
    Type: Application
    Filed: May 10, 2012
    Publication date: February 5, 2015
    Inventors: Xiyun Yan, Minmin Liang, Kelong Fan, Dongling Yang, Di Lu, Jing Feng, Demin Duan
  • Patent number: 8945857
    Abstract: The invention provides methods for isolating cells, particularly antibody-secreting cells that have a high likelihood of secreting antibodies specific for a desired antigen for the purpose of making monoclonal antibodies.
    Type: Grant
    Filed: June 30, 2006
    Date of Patent: February 3, 2015
    Inventor: John Schrader
  • Publication number: 20150031050
    Abstract: Uses and applications derived from the discovery of a novel binding site of IKK-?, such as method of screening a therapeutic agent as drug candidate for treating cancer, inflammation, or other diseases/disorders, are provided.
    Type: Application
    Filed: August 11, 2014
    Publication date: January 29, 2015
    Inventors: Liang LIU, Ting LI, Kam Wai WONG, Zhihong JIANG, Hua ZHOU